Claire Dossier, Stéphanie Bonneric, Véronique Baudouin, Thérésa Kwon, Benjamin Prim, Alexandra Cambier, Anne Couderc, Christelle Moreau, Georges Deschenes, Julien Hogan
BACKGROUND: B-cell depletion with rituximab induces sustained remission in children with steroid-dependent or frequently relapsing nephrotic syndrome. However, most patients relapse after B-cell recovery, and some patients do not achieve B-cell depletion. Obinutuzumab is a second-generation anti-CD20 antibody designed to overcome such situations in B-cell malignancies and was recently reported to be safe and effective in other autoimmune diseases affecting the kidneys. METHODS: We retrospectively report 41 children with steroid-dependent or frequently relapsing nephrotic syndrome treated with a single low-dose infusion of obinutuzumab at Robert-Debre Hospital between April 2018 and December 2020...
December 1, 2023: Clinical Journal of the American Society of Nephrology: CJASN